1. PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies of alirocumab 
Eric Bruckert, MD, Dean J. Kereiakes, MD, FACC, FSCAI, Michael J. Koren, MD, FACC, FAPCR, CPI, Michael J. Louie, MD, MPH, MSc, Alexia Letierce, PhD, Kathryn Miller, MS, Christopher P. Cannon, MD 
Journal of Clinical Lipidology 
Volume 13, Issue 3, Pages (May 2019)
DOI: /j.jacl
Copyright © Terms and Conditions

2. Journal of Clinical Lipidology 2019 13, 443-454DOI: (10. 1016/j. jacl
Copyright © Terms and Conditions

3. Figure 1
Overview of studies included in this pooled analysis (randomized population). * Rosuvastatin 20–40 mg, atorvastatin 40–80 mg, or simvastatin 80 mg daily, or lower doses with an investigator-documented reason eg, intolerance; OPTIONS I used atorvastatin 20–40 mg and OPTIONS II used rosuvastatin 10–20 mg. † Other LLT not allowed in COMBO II.‡ Dose adjustment from 75 to 150 mg Q2W at week 12 if LDL-C was ≥70 mg/dL at week 8 (or, in OPTIONS I, OPTIONS II, and ALTERNATIVE studies, ≥70 mg/dL for patients with prior CHD or ≥100 mg/dL with CHD risk equivalents). Study names/sponsor study numbers are shown in boxes together with duration of double-blind treatment periods, clinicaltrials.gov registration numbers, and details of alirocumab dose, control and number of patients in the randomized populations. Note that statin control arms from OPTIONS I, OPTIONS II, and ALTERNATIVE studies were not included. CHD, coronary heart disease; LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy; Q2W, every 2 weeks.
Journal of Clinical Lipidology  , DOI: ( /j.jacl )
Copyright © Terms and Conditions

4. Figure 2
Percentage change from baseline in LDL-C (A) and achieved LDL-C level (B) at week 24 in patients with or without prior MI/ischemic stroke (ITT analysis). *P < .0001 vs control. † Interaction P-value for percentage reduction in LDL-C (alirocumab minus control) for patients with vs without prior MI/ischemic stroke. Patients received maximally tolerated statins (rosuvastatin 20–40 mg, atorvastatin 40–80 mg, or simvastatin 80 mg daily), except for OPTIONS I (atorvastatin 20–40 mg) and OPTIONS II (rosuvastatin 10–20 mg), and ALTERNATIVE (no statins). ITT, intent-to-treat; LDL-C, low-density lipoprotein cholesterol; LS, least squares; MI, myocardial infarction; Q2W, every 2 weeks; SE, standard error.
Journal of Clinical Lipidology  , DOI: ( /j.jacl )
Copyright © Terms and Conditions

5. Figure 3
Proportion of patients (%) with or without prior MI/ischemic stroke achieving LDL-C <70 mg/dL at week 24 (mITT analysis). *P < .0001 vs control. †P < .001 vs control. LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; mITT, modified intent-to-treat; Q2W, every 2 weeks.
Journal of Clinical Lipidology  , DOI: ( /j.jacl )
Copyright © Terms and Conditions

6. Figure 4
Percentage change from baseline to week 24 in (A) non–HDL-C, (B) apoB, and (C) Lp(a) levels in patients with or without prior MI/ischemic stroke (ITT analysis). † Interaction P-value for percentage reduction in lipid/lipoprotein (alirocumab minus control) for patients with vs without prior MI/ischemic stroke. apoB, apolipoprotein B; ITT, intent-to-treat; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a); LS, least squares; MI, myocardial infarction; non–HDL-C, non–high-density lipoprotein cholesterol; Q2W, every 2 weeks; SE, standard error.
Journal of Clinical Lipidology  , DOI: ( /j.jacl )
Copyright © Terms and Conditions